【摘要】 三阴性乳腺癌(TNBC)的恶性程度与复发风险远高于其他类型乳腺癌,易出现其他脏器的转移。目前化疗依然是TNBC的主要治疗方式。紫杉类和蒽环类药物仍是TNBC辅助化疗和新辅助化疗方案的基石类药物。但是,TNBC复杂的异质性使得接受这些化疗方案的患者依然存在较高的复发率。临床上进行了多项探索,例如采用紫杉类和蒽环类药物密集给药方案,加用化疗药物如卡培他滨、铂类,以及新的治疗方法和药物,例如聚腺苷酸二磷酸核糖基聚合酶(PARP)抑制剂、免疫治疗、抗血管生成药物或PI3K/Akt/m TOR抑制剂等。同时,分子分型基础上的TNBC精准治疗策略代表了新的发展方向。本文将就TNBC的辅助及新辅助治疗的用药及各类方案进行深入讨论。更多还原

【Abstract】 The degree of malignancy and recurrence risk of triple negative breast cancer( TNBC) is much higher than that of other types of breast cancer. And TNBC is prone to metastasis to other organs. Currently,chemotherapy is still the main treatment for TNBC. Taxanes and anthracyclines are still the cornerstone drugs in TNBC adjuvant and neoadjuvant chemotherapy regimens.However,due to the complex heterogeneity of TNBC,there is still a high recurrence rate for patients receiving these chemotherapy regimens. To address this problem,a number of clinical trials have been carried out. For example,intensive administration of taxanes and anthracyclines was used. Chemotherapy drugs such as capecitabine and platinum were added; and new treatments and drugs such as polyadenylate ribosomal polymerase( PARP) inhibitors,immunotherapy,antiangiogenic drugs,or PI3 K/Akt/mTOR inhibitors were applied. At the same time, the TNBC precision treatment strategy based on molecular classification represents a new development direction. This article will discuss in depth the medication and various programs of TNBC’s adjuvant and neoadjuvant therapy.更多还原